Lördag 2 Augusti | 11:00:17 Europe / Stockholm

Prenumeration

2025-07-21 08:26:00

Redeye retains its positive view of CombinedX following a relatively soft Q2. The lowered headcount hurt sales and profitability. While we remain cautious regarding the market, we see some marginal expansion potential from efficiency.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/